Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.

Author: BarrettDavid A, BellJimmy D, JadoonKhalid A, O'SullivanSaoirse E, RatcliffeStuart H, StottColin, TanGarry D, ThomasE Louise

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Δ(9)-tetrahydrocannabivarin (THCV) was found to improve glycemic control in patients with type 2 diabetes. The study involved 62 patients with noninsulin-treated type 2 diabetes who were randomized to receive either THCV, cannabidiol (CBD), a combination of both, or placebo. THCV significantly decreased fasting plasma glucose and improved pancreatic β-cell function, adiponectin, and apolipoprotein A levels.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Cannabidiol (CBD) and Δ(9)-tetrahydrocannabivarin (THCV) are nonpsychoactive phytocannabinoids affecting lipid and glucose metabolism in animal models. This study set out to examine the effects of these compounds in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this rand...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2337/dc16-0650

データ提供：米国国立医学図書館（NLM）

Cannabinoids and Type 2 Diabetes: A Glimpse into a Potential Treatment

Type 2 diabetes, a metabolic disorder, affects millions worldwide. This study explores the potential of cannabidiol (CBD) and tetrahydrocannabivarin (THCV), nonpsychoactive components of cannabis, in managing glycemic and lipid parameters in individuals with type 2 diabetes.

Cannabinoids Show Promise in Managing Type 2 Diabetes

The study reveals that THCV, when compared to placebo, significantly decreased fasting plasma glucose and improved pancreatic β-cell function in individuals with type 2 diabetes. These findings suggest that THCV could offer a novel therapeutic approach for managing glycemic control in this population. While further research is needed, the study offers promising insights into the potential of cannabinoids in treating type 2 diabetes.

Potential for New Treatment Options

The study’s findings open new avenues for exploring cannabinoids as potential treatment options for type 2 diabetes. The potential of THCV to improve glycemic control is particularly encouraging, offering a potential alternative or addition to existing treatment approaches. Just as a desert traveler seeks a refreshing spring, individuals with type 2 diabetes might find relief and improved management through these natural compounds.

Dr. Camel's Conclusion

This research is like a desert explorer uncovering a hidden oasis of potential therapeutic benefits. The study’s findings suggest that cannabinoids, particularly THCV, could hold promise for managing type 2 diabetes. However, it’s important to note that further research is needed to confirm these findings and explore the optimal ways to harness the potential of these compounds. Just as a desert can hold both beauty and challenges, the world of cannabinoids offers both promise and uncertainty, necessitating careful exploration and understanding.

Date :
  1. Date Completed 2017-10-12
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

27573936

DOI: Digital Object Identifier

10.2337/dc16-0650

Related Literature

Article Analysis
・Effects of cannabidiol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.